ALBUQUERQUE, N.M.–AgilVax, Inc., a biopharmaceutical company developing targeted antibody-based products to treat multiple types of cancer in combination with chemotherapy, checkpoint, and KRAS inhibitors, announced that it closed an expansion of its Series A-1 financing with an additional investment of $1.5 million from its existing investors, bringing the total capital raised to nearly $10 million.

“This additional investment reflects the confidence of our existing investors and allows AgilVax to continue generating compelling preclinical data with our monoclonal antibody-drug conjugates targeting SLC7A11 (xCT),” stated Dr. Joseph Patti, President and Chief Executive Officer of AgilVax. Dr. Patti further stated, “xCT overexpression is often associated with KRAS mutations in several cancers and its biological role is involved with critical cellular metabolic changes that lead to tumor progression. AgilVax’s antibody-based therapeutics have shown the ability to reduce primary tumor formation and the number of lung metastases in an animal model illustrating the potential to create durable responses in patients suffering from various metastatic cancers.”

Ebetuel Pallares, PhD, AgilVax’s Chairman, said, “The team is making excellent progress developing their antibody-based programs for multiple oncology indications and we are excited to support this important research.”

About AgilVax

AgilVax is a New Mexico biopharmaceutical company that discovers and develops targeted antibody-based products to treat multiple types of cancer. The Company has three development programs; an antibody-drug conjugate targeting xCT, an unmodified monoclonal antibody targeting xCT, and AX09, a VLP-based xCT vaccine.